Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

So even a billion-dollar-or-so swing in Zepbound's future sales ... Additionally, Lilly could leverage specialty pharmacies or direct-to-patient models to bypass some PBM restrictions.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Eli Lilly is working on a new drug, orforglipron, an oral tablet taken once daily, with no dietary restrictions ... Eli Lilly's total sales between Mounjaro and Zepbound were slightly under ...

Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar sales still trail Wegovy ... the body and doesn't require dietary restrictions like oral semaglutide does ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale ... Zepbound and Mounjaro from competitor Eli Lilly.

The study involved a large clinical trial comparing the drugs that was funded by Eli Lilly, the maker of Zepbound ... option when regulators halted sales of copycat versions that sometimes ...